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CASE REPORT
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Calcinosis cutis is a condition characterized by the de-
position of calcium salts in the skin and subcutaneous 
tissues, and patients suffering from it encounter various 
connective tissue disorders, such as dermatomyositis (DM), 
scleroderma, and systemic lupus erythematosus. Although 
calcinosis cutis is frequently accompanied by juvenile 
dermatomyositis, rare cases have been reported in adult 
patients with DM. On the other hand, lichen sclerosus (LS) is 
a chronic inflammatory disease of the skin and mucosal 
surfaces. In the present report, we present a rare case of a 
71-year-old patient with DM accompanied by ulcerated 
calcinosis cutis and vulvar LS. (Ann Dermatol 23(S3) S375∼
S379, 2011)
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INTRODUCTION
Dermatomyositis (DM) is a rare multisystemic non-sup-
purative inflammatory disease of the skeletal muscles, 
characterized by typical skin lesions, and symmetric 
proximal extensor myopathy. Calcinosis cutis is frequently 
accompanied by juvenile dermatomyositis (JDM). Ulcera-
tion may be observed in the lesions of calcinosis cutis
1,2. 
Cases of the co-existence of ulcerated calcinosis cutis and 
adult DM have been rarely reported
3,4. The current case is 
presented due to the relatively rare incidence of ulcerated 
calcinosis cutis in patients with adult DM, as well as the 
co-existence of vulvar lichen sclerosus (LS), which has not 
been reported previously to the best of our knowledge. 
CASE REPORT
A 71-year-old woman was admitted to our hospital with 
complaints of wounds in both axillae and below the right 
breast over the past two months, as well as violet-colored 
edematous erythema on the upper eye lids, difficulties in 
walking, sitting, and lifting of the arms for the past 6 
months, dysphagia, and inability to urinate for the past 45 
days. The patient underwent surgery for stage IV adeno-
carcinoma of the ovary, and had a history of type-II 
diabetes mellitus. Dermatologic examination revealed 
ulcerated-nodular lesions in the bilateral axillary and right 
inframammary regions (Fig. 1), hard nodular lesions in the 
bilateral pectoral muscles, bilateral violet-colored ery-
thematous and edematous eyelids (Fig. 2), violet-colored/ 
hyperpigmented patches on the knees and elbows, and 
poikilodermatous eruptions on the anterior surface of the 
chest, scapular area and shoulders. An eroded, atrophic, 
depigmented patch was also observed on the labium 
minus and clitoris (Fig. 3). 
Histopathologic examination of a punch biopsy obtained 
from the patient’s poikilodermatous lesions demonstrated 
scattered vacuolar degeneration of the thin layer of or-
thokeratosis at the base of the epidermis, mild edema in DD Balcı, et al
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Fig. 5. Extensive lamellar calcification in the subcutaneous 
adipose tissue (H&E, ×40).
Fig. 4. Scattered vacuolar degeneration of the thin layer of 
orthokeratosis at the base of the epidermis, mild edema in the 
upper dermis, melanophages and perivascular lymphocytic 
infiltration (H&E, ×200).
Fig. 3. Eroded atrophic depigmented patch localized on the 
labium minus and clitoris.
Fig. 2. Bilateral violet-colored erythematous and edematous
eyelids.
Fig. 1. Ulcerated-nodular lesions localized on the axillary region.
the upper dermis, melanophages, and perivascular lym-
phocytic infiltration (Fig. 4). Histopathologic analysis of 
the excisional biopsy obtained from the nodular lesions in 
the pectoral region demonstrated a perivascular chronic 
inflammatory cell infiltration with papillomatous appea-
rance in the dermis and extensive lamellar calcification in 
the subcutaneous adipose tissue (Fig. 5). Histopathologic 
analysis of a punch biopsy taken from the depigmented 
lesions of the vulva revealed a thin layer of lamellar hyper-
keratosis with scattered atrophy, scattered acanthosis, 
papillomatous, scattered edema in the upper dermis, and 
patchy collagen deposition in the dermis. In addition to 
dilated and congested vessels, a mixed inflammatory cell 
infiltration was also observed (Fig. 6). These findings were 
consistent with DM, calcinosis cutis and LS, respectively. Lichen Sclerosus, Calcinosis Cutis and Dermatomyositis
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Fig. 6. A thin layer of lamellar hyperkeratosis with scattered 
atrophy, acanthosis, papillomatous and edema in the upper 
dermis, and patchy collagen deposition in the epidermis (H&E,
×100).
The esophageal passage graph performed to evaluate the 
dysphagia was normal. No pathologic findings were ob-
served in the cranial, cervical, abdomino-pelvic magnetic 
resonance imaging, thoracic computed tomography, mam-
mography, and breast ultrasonography (USG), which were 
performed due to a history of malignancy. 
The electromyography performed to investigate muscle 
weakness demonstrated findings of neuropathy and my-
opathy. The results of the direct urinary system graphy and 
abdominopelvic USG were within normal limits. The 
hemogram was consistent with the anemia of chronic 
disease. The aspartate aminotransferase, alanine amino-
transferase, creatine phosphokinase, calcium (Ca), and 
phosphate (P) levels were normal, whereas the lactate 
dehydrogenase level was high. The result of the antinu-
clear antibody test was negative. The patient was started 
on systemic prednisolone (60 mg/day), colchicine (1.5 
g/day), and hydroxychloroquine (400 mg/day). Topical 
treatment for the ulcerated area included a collagen-based 
wound dressing, pomade including collagenase, fusidic 
acid cream, and clobetasol 17-propionate cream for the 
vulva. On the 3rd week of treatment, some of the ulcer-
ated lesions regressed with epithelization, and lesions on 
the trunk and extremities almost completely healed with 
hyperpigmentation. Moreover, the edema and violet- 
colored erythema on the face faded mildly, and the 
nodular lesions significantly regressed. The treatment was 
continued for 6 weeks, but no improvement was observed 
in the lesions of the vulva. By the end of the treatment 
period, partial regression was observed in the patient’s 
skin lesions, but no improvement was reported, with 
difficulties in swallowing and muscle weakness. Total 
parenteral nutrition solution and enteral nutrition by naso-
gastric tube were initiated by the end of the 4th week due 
to progressive difficulty in swallowing. The patient was 
being monitored for recurrent catheter-related infections, 
blood glucose level and electrolyte imbalance, and died 
during the 6th week of treatment.
DISCUSSION
DM is an autoimmune connective tissue disorder cha-
racterized by typical skin lesions and symmetric idiopathic 
inflammatory myopathy. The disease affects both children 
and adults, and is more frequently encountered in women 
than in men. Violet-colored papules and plague spread 
over bony protrusions on the dorsa of the hands (Gottron’s 
papules), and symmetric, violaceous erythematous ma-
cules on the knees and elbows (Gottron’s sign) are 
pathognomonic of DM. Other skin lesions include peri-
orbital violaceous (heliotrope) erythema/edema, periun-
gual telangiectasia, erythema in a photosensitive distri-
bution, poikiloderma, and alopecia. In our patient, we 
observed periorbital violet-colored erythema and edema, 
violet-colored/hyperpigmented patches on the knees and 
elbows and poikilodermatous eruptions on the anterior 
surface of the chest, scapular areas, and shoulders
1-4.
In addition to skin involvement, DM is a systemic disease 
with skeletal muscle involvement, characterized by sym-
metric, proximal, and extensor myopathy, and it can be 
accompanied by arthritis, arthralgias, esophageal disease, 
or cardiopulmonary dysfunction
4. Our patient also pre-
sented with dysphagia associated with esophageal invol-
vement, and difficulties in walking, sitting, and lifting of 
the arms associated with proximal extensor myopathy.
The relationship of DM with cancer is well-known. The 
incidence of internal malignancy in patients with adult 
DM has been reported to range from 10∼50%. The most 
frequently reported malignancy is ovarian cancer, fol-
lowed by genitourinary malignancies and colon cancer
4,5. 
Our patient had a history of stage IV adenocarcinoma of 
the ovary, which had been diagnosed 4 years ago. The 
patient underwent surgery for malignancy and received 
six courses of chemotherapy.
The treatment of cutaneous lesions of DM involves the use 
of sun protection agents, topical corticosteroids, systemic 
hydroxychloroquine, quinacrine, low-dose methotrexate, 
and retinoids, whereas immunosuppressive agents, such 
as systemic steroids, methotrexate, azathioprine, intra-
venous immunoglobulin, cyclophosphamide, and cyclos-
porine are used for the treatment of muscle weakness and DD Balcı, et al
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systemic findings
1. Our patient was also started on com-
bined corticosteroid therapy and hydroxychloroquine 
treatment.
LS is a rarely encountered chronic inflammatory disease of 
the skin and mucosal surfaces, which most commonly 
involves the anogenital region. The exact cause of LS is 
unknown. Familial occurrence of LS suggests that LS may 
have a genetic link. LS is clinically characterized by poly-
gonal papules, and porcelain-white plaques, with atrophic 
fragile skin, fissures, erosions, telangiectasias, erythema, 
and different degrees of sclerosis in the anogenital region. 
It can also be observed in the other regions of the body. 
LS is most frequently observed in elderly women, al-
though it can be seen in any age group
6,7. 
Dyspareunia, urinary tract obstruction, constipation, infec-
tions secondary to ulceration and the development of 
squamous cell carcinoma associated with LS are the 
primary complications observed in women. The first 
choice of treatment is the application of ultrapotent topical 
corticosteroids
6,7. In our case, the complaint of inability to 
urinate was considered to be due to vulvar LS. Topical 
clobetasol 17-propionate cream was used for the vulva 
lesions.
Calcinosis cutis is an important complication of DM, 
characterized by the accumulation of hydroxyapatite cry-
stals and amorphous calcium phosphate in the skin and 
soft tissue
8. Although calcinosis cutis is mostly encoun-
tered in JDM, it is rare in adult onset chronic DM
9,10. 
Muller et al. reported the incidence of cutaneous cal-
cinosis as 20% and 74% among adults and children with 
DM, respectively
11. Cases of the co-existence of ulcerated 
calcinosis cutis and adult DM have been rarely repor-
ted
12,13. Calcinosis cutis appears as a late symptom and 
dystrophic calcifications are observed
11,14. Calcinosis cutis 
may sometimes lead to severe pain with marked weak-
ness, joint contractures, persistent infectious ulceration of 
the skin, cosmetic disorders
9, and muscular atrophy. In 
adults, lesions are frequently in the form of dermal or 
subcutaneous nodules and are usually observed in the 
sites of repeated microtrauma, such as the elbows, knees, 
and other acral areas
12,15. Large subcutaneous tumoral 
deposits may also form on the trunk of the body
4. The risk 
factors involved in the development of calcinosis cutis 
include delayed treatment and severity of the course of 
disease
16. In our case, ulcerated nodular lesions were seen 
in both bilateral axillary and right inframammary regions, 
as well as in bilateral pectoral regions. Our patient 
showed relatively early manifestation of calcinosis cutis, 
which may be related to delayed treatment and severe 
course of the disease. The patient was started on col-
chicine (1.5 g/day).
Spontaneous regression has been reported in some 
patients with calcinosis; however, no effective treatment 
modality has yet been suggested. On the other hand, 
various degrees of success have been reported with 
bisphosphonates, probenecid, warfarin, aluminum hyd-
roxide, colchicine, diltiazem, surgical excision, and intral-
esional steroid either as monotherapy or in combination, 
depending on the clinical circumstances
9,13,15,17-19. 
Prednisolone (60 mg/day), colchicine (1.5 g/day), and 
hydroxychloroquine (400 mg/day) were administered to 
the patient with severe systemic and cutaneous symptoms. 
Moreover, topical treatment with a collagen-based wound 
dressing that was a pomade including collagenase and 
fusidic acid cream, was applied to the ulcerated areas. We 
observed that some of the ulcerated nodular lesions 
regressed with epithelization, while skin lesions on the 
face, trunk, and extremities significantly regressed. There 
are studies reporting successive results in the treatment of 
cutaneous and muscle weakness symptoms of DM with 
steroid therapy within one to several months, suggesting 
the maintenance of steroid therapy for 6 months to 2 years 
through dose reduction
1,2. Various case reports have 
demonstrated that regression of calcinosis cutis co-existing 
with juvenile or adult DM and localised linear scle-
roderma is observed within a mean period of 4 months 
with colchicine treatment, over 2.5 years with diltiazem 
treatment, 8 months with aluminum hydroxide treatment, 
and 2 years with hydroxychloroquine, azathioprine and 
prednisolone treatments
12,18-20. In our case, the patient 
died due to secondary infections and metabolic disorders, 
we could not perform long-term monitoring to observe a 
complete clinical response to systemic therapy.
Previous reports have documented that DM/polymyositis 
may be associated with other autoimmune connective 
tissue diseases such as systemic lupus erythematosus, 
scleroderma, rheumatoid arthritis, Sjögren’s syndrome and 
inflammatory, dermal and subcutaneous connective tissue 
disease such as morphea profunda
1,21. 
Here, we demonstrated the co-existence of ulcerated cal-
cinosis cutis in a patient with adult DM, as well as the 
co-existence of vulvar LS, which was the first reported 
case to the best of our knowledge. The coexistence of 
both diseases may be incidentally, inevitably or immune 
mediated. In our case, there are two possible explanations 
of the relationship between DM and LS. First, DM patients 
have some autoantibodies resulting from an immune- 
mediated process. DM patients have antisynthetase anti-
bodies which are often associated with overlap syn-
dromes. IgG autoantibodies against extracellular matrix 
protein 1 are involved in the pathogenesis of LS. A likely 
relationship with autoimmunity is also possible. LS may Lichen Sclerosus, Calcinosis Cutis and Dermatomyositis
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be associated with the HLA-DQ7 region of MHC class II 
antigen, which is related to an increased risk of auto-
immune diseases. Secondly, a 19% overlap rate has been 
reported in adult DM cases with other autoimmune con-
nective tissue diseases. The most frequent overlap in adult 
DM is scleroderma. A coexistence with DM and morphea 
profunda has also been reported
21. LS is known to be 
closely related to morphea. Scleroderma, morphea and LS 
are a group of diseases which are associated with dermal 
sclerosis
1,21,22. 
Even though the exact relationship between DM and LS is 
not apparent, this case report presents a rare connective 
tissue disease which affects the upper dermis and epi-
dermis, which may coexist with DM.
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